Analysts’ Recent Ratings Changes for Thermo Fisher Scientific (TMO)

A number of firms have modified their ratings and price targets on shares of Thermo Fisher Scientific (NYSE: TMO) recently:

• 5/14/2026 – Thermo Fisher Scientific was given a new $490.00 price target by Royal Bank Of Canada. They now have a “sector perform” rating on the stock.
• 5/14/2026 – Thermo Fisher Scientific was upgraded by Royal Bank Of Canada to “hold”.
• 5/9/2026 – Thermo Fisher Scientific was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/8/2026 – Thermo Fisher Scientific had its price target lowered by Wells Fargo & Company from $675.00 to $615.00. They now have an “overweight” rating on the stock.
• 4/27/2026 – Thermo Fisher Scientific had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $620.00 price target on the stock.
• 4/24/2026 – Thermo Fisher Scientific was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 4/24/2026 – Thermo Fisher Scientific had its price target lowered by Stifel Nicolaus from $700.00 to $600.00. They now have a “buy” rating on the stock.
• 4/24/2026 – Thermo Fisher Scientific had its price target lowered by Robert W. Baird from $653.00 to $639.00. They now have an “outperform” rating on the stock.
• 4/14/2026 – Thermo Fisher Scientific had its price target lowered by Barclays PLC from $650.00 to $625.00. They now have an “overweight” rating on the stock.
• 4/8/2026 – Thermo Fisher Scientific had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 3/27/2026 – Thermo Fisher Scientific is now covered by DZ Bank AG. They set a “buy” rating and a $610.00 price target on the stock.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were given a dividend of $0.47 per share. The ex-dividend date was Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Insider Activity

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.